TABLE 2.
Clinicopathological Correlation of PERK and P-eIF2α Expression in Patients With PDAC
| Characteristics | PERK-low (%) (n = 42) |
PERK-high (%) (n = 42) |
P | p-eIF2α-low (%) (n = 37) |
p-eIF2α-high (%) (n = 47) |
P |
|---|---|---|---|---|---|---|
| Sex | 0.66 | 0.18 | ||||
| Female | 16 (38.1) | 18 (42.9) | 12 (32.4) | 22 (46.8) | ||
| Male | 26 (61.9) | 24 (57.1) | 25 (67.6) | 25 (53.2) | ||
| Tumor differentiation | 0.35 | 0.46 | ||||
| Well-Moderate | 31 (73.8) | 27 (64.3) | 24 (64.9) | 34 (72.3) | ||
| Poor | 11 (26.2) | 15 (35.7) | 13 (35.1) | 13 (27.7) | ||
| pT (AJCC 8th edition) | 0.46 | 0.75 | ||||
| pT1 | 8 (19.1) | 4 (9.5) | 5 (13.5) | 7 (14.9) | ||
| pT2 | 29 (69.0) | 32 (76.2) | 26 (70.3) | 35 (74.5) | ||
| pT3 | 5 (11.9) | 6 (14.3) | 6 (16.2) | 5 (10.6) | ||
| pN (AJCC 8th edition) | 0.20 | 0.81 | ||||
| pN0 | 11 (26.2) | 5 (11.9) | 6 (16.2) | 10 (21.3) | ||
| pN1 | 16 (38.1) | 16 (38.1) | 14 (37.8) | 18 (38.3) | ||
| pN2 | 15 (35.7) | 21 (50.0) | 17 (46.0) | 19 (40.4) | ||
| Margin | 0.29 | 0.49 | ||||
| Negative | 39 (92.9) | 36 (85.7) | 34 (91.9) | 41 (87.2) | ||
| Positive | 3 (7.1) | 6 (14.3) | 3 (8.1) | 6 (12.8) | ||
| Recurrence/metastasis | 0.10 | 0.01 | ||||
| No | 17 (40.5) | 9 (21.4) | 17 (45.9) | 9 (19.1) | ||
| Yes | 25 (59.5) | 33 (78.6) | 20 (54.1) | 38 (80.9) |